Insight Molecular Diagnostics (IMDX) Non-Current Assets (2015 - 2026)

Insight Molecular Diagnostics has reported Non-Current Assets for 12 years, with the latest figure at $9.9 million in Q1 2026.

• Quarterly Non-Current Assets fell 58.87% year-over-year to $9.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.6 million (down 62.51% YoY) and the FY2025 annual result came in at $10.4 million, down 55.19% from the prior year.
• Non-Current Assets retreated to $9.9 million in Q1 2026 per IMDX's latest filing, from $10.4 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $121.7 million in Q2 2022 and troughed at $9.9 million in Q1 2026.
• A 5-year average of $59.4 million and a median of $64.7 million in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets soared 82.98% in 2022, then plunged 65.54% in 2025.
• Over 5 years, Non-Current Assets stood at $74.6 million in 2022, then decreased by 13.9% to $64.2 million in 2023, then sank by 63.67% to $23.3 million in 2024, then slumped by 55.19% to $10.4 million in 2025, then dropped by 5.17% to $9.9 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $9.9 million, $10.4 million, and $22.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.